Cidara Therapeutics Earnings Estimate
| CDTX Stock | USD 21.80 0.25 1.13% |
Cidara |
Cidara Therapeutics Earnings Estimation Breakdown
The calculation of Cidara Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Cidara Therapeutics is estimated to be -3.4725 with the future projection ranging from a low of -5.45 to a high of -1.47. Please be aware that this consensus of annual earnings estimates for Cidara Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-5.45 Lowest | Expected EPS | -1.47 Highest |
Cidara Therapeutics Earnings Projection Consensus
Suppose the current estimates of Cidara Therapeutics' value are higher than the current market price of the Cidara Therapeutics stock. In this case, investors may conclude that Cidara Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Cidara Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 6 | 42.82% | -5.38 | -3.4725 | -26.82 |
Cidara Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Cidara Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Cidara Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Cidara Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Cidara Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Cidara Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Cidara Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Cidara Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Cidara Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-03-07 | 2024-12-31 | -3.6725 | -5.38 | -1.7075 | 46 | ||
2024-10-31 | 2024-09-30 | -4.25 | -2.45 | 1.8 | 42 | ||
2024-08-13 | 2024-06-30 | -3.22 | -19.99 | -16.77 | 520 | ||
2024-05-15 | 2024-03-31 | -0.2 | -2.28 | -2.08 | 1040 | ||
2024-03-27 | 2023-12-31 | -0.1 | -0.04 | 0.06 | 60 | ||
2023-11-02 | 2023-09-30 | -0.16 | -0.09 | 0.07 | 43 | ||
2023-08-03 | 2023-06-30 | -0.13 | -0.14 | -0.01 | 7 | ||
2023-05-11 | 2023-03-31 | -0.04 | 0.03 | 0.07 | 175 | ||
2023-03-23 | 2022-12-31 | -0.17 | -0.19 | -0.02 | 11 | ||
2022-11-03 | 2022-09-30 | 0.18 | 0.17 | -0.01 | 5 | ||
2022-08-09 | 2022-06-30 | -0.28 | -0.19 | 0.09 | 32 | ||
2022-05-11 | 2022-03-31 | -0.29 | -0.27 | 0.02 | 6 | ||
2022-03-07 | 2021-12-31 | -0.34 | -0.26 | 0.08 | 23 | ||
2021-11-10 | 2021-09-30 | -0.36 | -0.37 | -0.01 | 2 | ||
2021-08-12 | 2021-06-30 | -0.08 | 0.18 | 0.26 | 325 | ||
2021-05-13 | 2021-03-31 | -0.26 | -0.39 | -0.13 | 50 | ||
2021-02-25 | 2020-12-31 | -0.24 | -0.49 | -0.25 | 104 | ||
2020-11-05 | 2020-09-30 | -0.38 | -0.41 | -0.03 | 7 | ||
2020-08-13 | 2020-06-30 | -0.28 | -0.45 | -0.17 | 60 | ||
2020-05-13 | 2020-03-31 | -0.34 | -0.46 | -0.12 | 35 | ||
2020-03-04 | 2019-12-31 | -0.43 | -0.42 | 0.01 | 2 | ||
2019-11-07 | 2019-09-30 | -0.26 | 0.08 | 0.34 | 130 | ||
2019-08-08 | 2019-06-30 | -0.57 | -0.49 | 0.08 | 14 | ||
2019-05-09 | 2019-03-31 | -0.6 | -0.6 | 0.0 | 0 | ||
2019-02-28 | 2018-12-31 | -0.59 | -0.44 | 0.15 | 25 | ||
2018-11-08 | 2018-09-30 | -0.6 | -0.49 | 0.11 | 18 | ||
2018-08-08 | 2018-06-30 | -0.66 | -1.13 | -0.47 | 71 | ||
2018-05-10 | 2018-03-31 | -0.64 | -0.8 | -0.16 | 25 | ||
2018-02-27 | 2017-12-31 | -0.76 | -0.69 | 0.07 | 9 | ||
2017-11-08 | 2017-09-30 | -0.94 | -0.73 | 0.21 | 22 | ||
2017-08-09 | 2017-06-30 | -0.88 | -0.99 | -0.11 | 12 | ||
2017-05-10 | 2017-03-31 | -0.88 | -0.8 | 0.08 | 9 | ||
2017-03-15 | 2016-12-31 | -0.79 | -0.88 | -0.09 | 11 | ||
2016-11-10 | 2016-09-30 | -0.88 | -0.88 | 0.0 | 0 | ||
2016-08-11 | 2016-06-30 | -0.76 | -0.85 | -0.09 | 11 | ||
2016-05-12 | 2016-03-31 | -0.74 | -0.71 | 0.03 | 4 | ||
2016-03-18 | 2015-12-31 | -0.7 | -0.72 | -0.02 | 2 | ||
2015-11-16 | 2015-09-30 | -0.57 | -0.67 | -0.1 | 17 | ||
2015-08-11 | 2015-06-30 | -0.57 | -0.59 | -0.02 | 3 | ||
2015-05-21 | 2015-03-31 | -0.7 | -5.92 | -5.22 | 745 |
About Cidara Therapeutics Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Cidara Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Cidara Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Cidara Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -611.3 M | -580.7 M | |
| Retained Earnings Total Equity | -366.3 M | -348 M | |
| Earnings Yield | (1.00) | (1.04) | |
| Price Earnings Ratio | (1.01) | (1.06) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.